Company Overview

Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient’s needs.

We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  

HBM’s efforts are driven by our vision of delivering “Innovative Medicines for Healthy Life”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.

view more
Harbour Mice®

We are building a robust pipeline with our integrated discovery and development platform, that enables us to develop novel antibodies differentiated by their activity against multiple disease targets, potency, and safety profiles.

view more
Pipeline
Immunology
Project(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

Batoclimab HBM9161(Hanall)

FcRn

ITP

GO

MG

NMOSD

Second Wave of Indications

Greater
China

Greater
China

Greater
China

Greater
China

Greater
China

view more

Tanfanercept HBM9036(Hanall)

TNFα

Dry Eye Disease

Greater
China

HBM9378

undisclosed

undisclosed

undisclosed

HBM9022(AbbVie; Utrecht University; Erasmus MC)

SARS-COV-2

COVID-19

Global license to AbbVie

Oncology
Project(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

HBM4003

CTLA-4

Advanced Solid Tumors

Advanced Melanoma&Other Solid Tumors

Advanced NSCLC&Other Solid Tumors

Global

Global

Global

HBM9302(Ichnos)

HER2xCD3

Breast Cancer and Gastric Cancer

Greater China

HBM1007

CD73

Solid Tumors

Global

HBM1029

Claudin 18.2

Solid Tumors

Ex-Greater China

HBM7020

BCMAxCD3

Multiple Myeloma

Ex-Greater China

HBM7015

PD-L1xTGF-β

Solid Tumors

Ex-Greater China

HBM7008

B7H4x4-1BB

Solid Tumors

Global

HBM1022

CCR8

Solid Tumors

Global

  • HBM

  • Partner

  • Directly Initiate PH 3 Study

  • Registrational Clinical Trial

  • Monotherapy

  • + PD-(L )1

Target and other details not disclosed due to commercial sensitivity

Partnership Models

Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company. Harbour BioMed has built up global R&D centers within USA, Europe and China.

view more
  • 01

    Co-Discovery/Co-Development

    Harbour BioMed is interested in combining its discovery capabilities, including its own Harbour Mice® (transgenic mice) Platform Technology, for generating fully human antibodies, and its expertise in clinical development, with potential partners’ unique resources and expertise to co-discovery/co-development biotherapeutics.

    View more
  • 02

    Licensing

    · Out-Licensing

    Utilizing the world renowned Harbour Mice® Platform Technology, Harbour BioMed has discovered many best-in-class, first-in-class therapeutic candidates that are in different stages of development. Out-Licensing of certain programs allows Harbour BioMed  to maximize the value of our assets and concentrate on certain programs, while ensuring patients to have access to all potential therapeutics.

     

    View more

    · In-Licensing

    Harbour BioMed is interested in acquiring or obtaining regional rights to molecules from other biotech and pharma companies that can address high unmet medical needs to enhance our portfolio and pipeline in the fields of immuno-oncology and immunological diseases.

    View more

    · Technology Licensing

    The Harbour Mice®Platform Technology, which includes both the H2L2 and HCAb transgenic mice platforms, have been widely used by over 40forty companies and academic institutionscenters. The platforms were engineered to produce high quality, highly diverse and fully human antibodies, through natural process of in vivo maturation from carefully selected human immunoglobulin transgenes.


    Currently, there are at least 6 antibodies that are generated from our H2L2/HCAb platforms and have entered into human clinical trials.  Besides, over 200 therapeutic candidates discovered from the H2L2/HCAb platforms are in pre-clinical study stages.

     

    View more
  • 03

    Academic Collaboration

    Combining the Harbour Mice® Platform Technology with academic institutes’ core strengths in early stage research and discovery is an innovative way to rapidly move attractive therapeutic candidates into the next phase of clinical development.

    View more
  • 04

    Joint Venture

    With highly selected partners who have unique knowledge and insights on special diseases or technology areas, we may choose to create joint ventures with them to explore highly innovative programs to address high unmet medical needs. We have initiated a few JV projects with an aim for broad technology and resource pooling and collaboration in the joint discovery, development and commercialization of the assets generated on our Harbour antibody platforms for treatment of rare diseases

    View more